Skip to main content

Table 3 Characteristics in the One Subject With Treatment-Emergent Tardive Dyskinesia as Per Defined Research Criteria

From: Evaluating movement disorders in pediatric patients receiving risperidone: a comparison of spontaneous reports and research criteria for TD

Gender

Male

Age

10 y

Diagnosis

Oppositional defiant disorder

Intellligence quotient (IQ)

59

NCBRF total score

  

   Baseline

33

   Endpoint

31

Time point

Risperidone dose (mg/day)

Dyskinesia score*

   Baseline

0.000

3

   Week 1

0.343

3

   Week 2

1.200

3

   Week 3

1.814

3

   Week 4

1.900

3

   Week 8

1.784

---

   Week 12

1.300

4

   Week 16

1.300

7

   Week 20

1.300

7

   Week 24

1.300

1

   Week 36

1.300

2

   Week 48

1.300

0

  1. NCBRF indicates Nisonger Child Behavior Rating Form.
  2. *Extrapyramidal Symptom Rating Scale (ESRS) physician's examination for dyskinesia, items E51–57.